

## SUPPLEMENTAL FORM 8 (OPEN POSITIONS)

### DETAILS OF OPEN STOCK-SETTLED DERIVATIVE (INCLUDING OPTION) POSITIONS, AGREEMENTS TO PURCHASE OR SELL ETC.

Note 5(i) on Rule 8 of the Takeover Code (the "Code")

#### 1. KEY INFORMATION

Full name of person making disclosure:	Nomura Holdings Inc.
Name of offeror/offeree in relation to whose relevant securities the disclosure relates:	Takeda Pharmaceutical Company Limited

#### 2. STOCK-SETTLED DERIVATIVES (INCLUDING OPTIONS)

Class of relevant security	Product description <i>e.g. call option</i>	Written or purchased	Number of securities to which option or derivative relates	Exercise price per unit	Type <i>e.g. American, European etc.</i>	Expiry date
Ordinary	Call	Purchased	-6,100	4,910	European	3-Dec-18
Ordinary	Call	Purchased	-21,700	4,847	European	7-Jun-21
Ordinary	Put	Purchased	-11,800	4,460	European	10-Jan-19
Ordinary	Put	Purchased	-6,000	4,727	European	31-July-20
Ordinary	Put	Purchased	-6,500	4,564	European	30-Aug-21
Ordinary	Put	Purchased	-10,300	4,827	European	28-Dec-21
Ordinary	Put	Purchased	-22,900	4,350	European	21-Jun-23
Ordinary	Put	Purchased	-6,400	4,626	European	11-Jul-23
Ordinary	Put	Purchased	-21,000	4,739	European	4-Aug-23

#### 3. AGREEMENTS TO PURCHASE OR SELL ETC.

Full details should be given so that the nature of the interest or position can be fully understood:

*It is not necessary to provide details on a Supplemental Form (Open Positions) with regard to cash-settled derivatives.*

*The currency of all prices and other monetary amounts should be stated.*

*The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.*

*The Code can be viewed on the Panel's website at [www.thetakeoverpanel.org.uk](http://www.thetakeoverpanel.org.uk).*